The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Emily Sonestedt

Emily Sonestedt

Associate senior lecturer

Emily Sonestedt

Plant foods, plasma enterolactone and breast cancer - with a focus on estrogen receptor status and genetic variation

Author

  • Emily Sonestedt

Summary, in English

Diets high in fibre have previously been associated with decreased risk of breast cancer in the Malmö Diet and Cancer cohort. Several potent compounds may exist in high-fibre diets that might protect against breast cancer, for example lignans. Plant lignans are converted to enterolactone by the gut microflora and are similar in structure to estrogens. Enterolactone may interact with the estrogen receptors (ERs) and, therefore, inhibit the effect of estrogens.



The aim of this doctoral project was to prospectively examine if plant food intakes and enterolactone blood concentrations were associated with breast cancer, and to examine if the association differed depending on ER status of the tumours or variation in the ER genes. Information (including high validity dietary data) from the Malmö Diet and Cancer cohort with baseline examinations from 1991 to 1996 was used. Among 15,773 women, 45-73 years at baseline, without prevalent cancer, 544 women were diagnosed with breast cancer until 31 December 2004.



High intakes of high-fibre bread were associated with decreased risk of breast cancer. When restricting the analyses to individuals with suggested more stable food habits, a decreased breast cancer risk were also observed with high intakes of fruit, berries and vegetables. High-fibre bread and fruit and berries were the main dietary determinants of enterolactone concentration. In addition, obesity and smoking was associated with lower enterolactone concentrations. High enterolactone concentrations (>16 nmol/L) was associated with decreased breast cancer risk. When stratifying for fibre intake, a decreased breast cancer risk with high enterolactone concentration was only observed among individuals with high fibre intakes. Relatively high variation of enterolactone within and between individuals was observed; the association between enterolactone and risk of breast cancer is likely attenuated. The reduced breast cancer risk with high enterolactone concentrations was only observed for ERα-positive and ERβ-negative tumours. Breast cancer risk was not significantly associated with any of the selected polymorphisms in the ERα and ERβ genes. However, the protective effect of high enterolactone concentration was seen in subgroups of the individuals with specific genetic variants, and a tendency towards an interaction between a polymorphism in intron 3 of the ERα gene and enterolactone concentrations was observed.



In conclusion, a high-fibre diet including high-fibre bread, fruit, berries and vegetables will likely reduce the risk of breast cancer in middle aged and older women. The protective effect of a high-fibre diet might be due to its content of lignans.

Department/s

  • Nutrition Epidemiology
  • Diabetes - Cardiovascular Disease

Publishing year

2008

Language

English

Publication/Series

Lund University Faculty of Medicine Doctoral Dissertation Series

Volume

2008:128

Document type

Dissertation

Publisher

Department of Clinical Sciences, Lund University

Topic

  • Clinical Medicine

Keywords

  • plant foods
  • breast cancer
  • fibre
  • epidemiology
  • lignans
  • enterolactone
  • plasma
  • estrogen receptor α
  • estrogen receptor β
  • polymorphisms
  • reliability
  • nutrition
  • prospective

Status

Published

Research group

  • Nutrition Epidemiology
  • Diabetes - Cardiovascular Disease

Supervisor

  • Elisabet Wirfält

ISBN/ISSN/Other

  • ISSN: 1652-8220
  • ISBN: 978-91-86059-81-1

Defence date

19 December 2008

Defence time

13:00

Defence place

Lecture Hall, Clinical Research Centre, Malmö University Hospital

Opponent

  • Anna Winkvist (Professor)